{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:42Z","timestamp":1791993942793,"version":"4.4.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fabry disease (FD) is a rare lysosomal storage disease, caused by mutations in the gene encoding the enzyme \u03b1-galactosidase A (\u03b1-Gal A). Cardiac involvement is one of the main causes of death and it is characterized by progressive concentric left ventricular hypertrophy (LVH), which in most cases is symmetric. Mild thickening of the left-sided valves is seen in as many as a quarter of patients. Severe aortic stenosis is an extremely rare disorder in FD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>In this report, we describe the case of a 57-year-old male, who was diagnosed with a cardiac variant of FD 10 years ago. Since the patient had severe LVH, he was started on enzyme replacement therapy when he was 47\u2009years old with an intravenous infusion of 0.2\u2009mg\/kg of agalsidase alpha every 14\u2009days. The patient remained stable and asymptomatic for 9\u2009years, until he presented with dyspnoea in New York Heart Association functional class II\u2013III and severe aortic stenosis (aortic valve area: 0.97 cm2) together with severe systolic dysfunction [ejection fraction (EF): 29%]. Because of the patient\u2019s comorbidities and high surgical risk, he underwent successful transfemoral transcatheter aortic valve implantation (TAVI). At 2\u2009months following TAVI, the patient was asymptomatic and, in spite of his Fabry cardiomyopathy, the EF had increased to 45%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>To our knowledge, this is the first case in the literature to demonstrate a rapid progression of aortic stenosis with severe impairment of left ventricular function and worsening in functional class in a patient with FD, who following TAVI improved his EF, with disappearance of symptoms and ventricular arrhythmias.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytab124","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T05:18:27Z","timestamp":1623907107000},"source":"Crossref","is-referenced-by-count":6,"title":["Rapidly progressive aortic stenosis treated with transcatheter aortic valve implantation in a patient with Fabry disease: a case report"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-1971","authenticated-orcid":false,"given":"Mar\u00eda C","family":"Saccheri","sequence":"first","affiliation":[{"name":"Division of Cardiology, Cardiology Department, Hospital of the Government of the City of Buenos Aires \u201cDr. Cosme Argerich\u201d, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-1173","authenticated-orcid":false,"given":"Tom\u00e1s F","family":"Cianciulli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiology Department, Hospital of the Government of the City of Buenos Aires \u201cDr. Cosme Argerich\u201d, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico L","family":"Blanco","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiology Department, Hospital of the Government of the City of Buenos Aires \u201cDr. Cosme Argerich\u201d, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo I","family":"Blanco","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiology Department, Hospital of the Government of the City of Buenos Aires \u201cDr. Cosme Argerich\u201d, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"2021082416315427900_ytab124-B1","first-page":"440","article-title":"Fabry disease-often seen, rarely diagnosed","volume":"106","author":"Hoffmann","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"2021082416315427900_ytab124-B2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"2021082416315427900_ytab124-B3","first-page":"38","article-title":"Cardiac abnormalities in Anderson-Fabry disease and Fabry\u2019s cardiomyopathy","volume":"22","author":"Morrissey","year":"2011","journal-title":"Cardiovasc J Afr"},{"key":"2021082416315427900_ytab124-B4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry\u2019s disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"2021082416315427900_ytab124-B5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"2021082416315427900_ytab124-B6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet Med"},{"key":"2021082416315427900_ytab124-B7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"2021082416315427900_ytab124-B8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.carpath.2009.10.003","article-title":"The heart in Fabr\u2019s disease","volume":"20","author":"Sheppard","year":"2011","journal-title":"Cardiovasc Pathol"},{"key":"2021082416315427900_ytab124-B9","first-page":"w02066","article-title":"Surgical treatment of severe aortic valve stenosis with concomitant Fabry disease","volume":"22","author":"Vlachou","year":"2019","journal-title":"Cardiovasc Med"},{"key":"2021082416315427900_ytab124-B10","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2021082416315427900_ytab124-B11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.echo.2016.11.014","article-title":"Right ventricular hypertrophy, systolic function, and disease severity in Anderson-Fabry Disease: an echocardiographic study","volume":"30","author":"Graziani","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"2021082416315427900_ytab124-B12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ultrasmedbio.2008.10.010","article-title":"Heart valve involvement in Fabry cardiomyopathy","volume":"35","author":"Weidemann","year":"2009","journal-title":"Ultrasound Med Biol"},{"key":"2021082416315427900_ytab124-B13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.echo.2020.11.015","article-title":"Excess mortality associated with progression rate in asymptomatic aortic valve stenosis","volume":"34","author":"Benfari","year":"2021","journal-title":"J Am Soc Echocardiogr"},{"key":"2021082416315427900_ytab124-B14","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1253\/circj.CJ-16-0333","article-title":"Predictors of rapid progression and clinical outcome of asymptomatic severe aortic stenosis","volume":"80","author":"Nishimura","year":"2016","journal-title":"Circ J"},{"key":"2021082416315427900_ytab124-B15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.echo.2020.12.012","article-title":"Aortic stenosis progression: Doppler echocardiography shifted the paradigm","volume":"34","author":"Otto","year":"2021","journal-title":"J Am Soc Echocardiogr"},{"key":"2021082416315427900_ytab124-B16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ehjci\/jew335","article-title":"Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"18","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/6\/ytab124\/39889248\/ytab124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/6\/ytab124\/39889248\/ytab124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T16:32:53Z","timestamp":1629822773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytab124\/6301260"}},"subtitle":[],"editor":[{"given":"Giulio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Claudio","family":"Montalto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Giulio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Daniel","family":"Tardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Mariame","family":"Chakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytab124","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,5,29]]},"article-number":"ytab124"}}